Welcome to Bowel Disease UK, our small (but mighty) charity which is focussed on raising much needed funds for research into Bowel cancer, Ulcerative colitis and Crohn’s disease. We current have some really exciting research going on looking into the amazing benefits of Artesunate, sweet wormwood extract, in improving the lives of people with bowel cancer and Crohn’s disease. Read all about it over on our research page.
Crohn's Disease, also known as regional enteritis, is an inflammatory disease of the intestines that affect any part of the gastrointestinal tract from the mouth to the anus, causing a wide variety of symptoms.
It primarily causes abdominal pain, diarrhoea (which may be bloody if inflammation is at its worst), vomiting or weight loss but may also cause complications outside the gastointestinal tract such as skin rashes, arthritis, inflammation of the eye, fatigue and lack of concentration.
Bowel Disease UK
To watch more videos about what we do and why we do it, visit our YouTube channel.
All the latest
COVID19 Research Update
Due to the effect of the COVID19 pandemic, the NeoART study (UK) and NeoART-V mirror study (Vietnam) have had to be paused. However both are now in the process of reopening and hope to be recruiting patients again in the next few months.
Whilst patient trials were put on hold, scientific lab work has continued. The team were able to carry out research to help identify cancer pathways targeted by Artesunate, that may explain the potential anticancer effects of this class of antimalarials.
We are excited to be listed on Amazon Smile!
By selecting Bowel Disease UK as your charity of choice when you shop with Amazon Smile, Amazon will donate 0.5% of your eligible purchases to the charity. It's a fantastic scheme for anyone who shops with Amazon, to raise money at no extra cost.
Phase II Artesunate Trial Approved
Following the success of the phase I clinical trial for Artesunate at St. George's hospital, we are excited to be funding a second larger trial which if successful could provide an effective, affordable treatment to reduce the risk of patients with bowel cancer having a reoccurrence after surgery.
This phase II trial has just been approved by the relevant boards and is now underway with the participating patients.
For more information, see our research page.